Last week, Sysnav Healthcare participated in the CNS Summit in Boston, engaging in insightful discussions with pharma and biotech leaders, CROs, investigator sites, and patient advocates dedicated to advancing precision measurement in drug development.
Across the sessions and the hallway discussions, one question kept coming up: How do we bring better drugs to patients faster?
The Power of Endpoint Choice
Endpoint choice is a big part of the answer. We need measures that are meaningful to patients and precise enough to detect early changes, so sponsors can react sooner, make decisions with confidence, and generate robust regulatory-grade evidence.
That’s what Syde® and Stride Velocity 95th Centile (SV95C) are built to deliver, a real-world view of how patients move in their daily lives, with the precision to back it up.
Analytical Validation in Neuromuscular and Neurological Disorders
Our latest analytical validation data, presented at the Summit, covers 100 patients across multiple neuromuscular and neurological indications.
The results showed strong precision, with stride velocity clocking within 0.7 cm/s of the reference standard.
We are grateful to all who participated in these discussions, and to the CNS Summit leadership for hosting this event.
Download our CNS poster here!
